Article

March 1, 2002

HIFU evaluated as second-line treatment for prostate Cancer

Bangkok, Thailand - High-intensity focused ultrasound (HIFU) may serve as an alternative, second-line treatment for prostate cancer patients who are poor candidates for more common primary treatment modalities

Related Content

May 13th 2025

Long-term data point to durable efficacy of Optilume for urethral strictures

Hannah Clarke

The freedom from re-intervention rate was 71%.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com

May 11th 2025

We got a little MIST-y at this year’s AUA Annual Meeting

Garrett D. Pohlman, MD

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com

May 9th 2025

Durvalumab plus BCG significantly improves DFS in NMIBC

Benjamin P. Saylor Hannah Clarke

The data are to be presented at an upcoming medical conference.